Articles
5 June 2009
Vol. 1 No. 11: Thalidomide in the treatment of multiple myeloma, Sydney, 10 April 2005
https://doi.org/10.4081/hmr.v1i11.354

Panel Discussion

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
134
Views
196
Downloads

Authors

Dr. Joshua
support@pagepress.org
Dr. Joshua, Symposium Chair: Patients commonly ask about the risks associated with thalidomide and whether they should take the drug early or wait until relapse occurs. Will early or late therapy make a difference for patients? Dr. San Miguel: It is probably better to start thalidomide treatment early, but we have no data to support that recommendation. Several studies are under way to address this question.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Panel Discussion. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 1(11). https://doi.org/10.4081/hmr.v1i11.354